IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
IDEAYA Biosciences (Nasdaq: IDYA) said it will present three ESMO 2026 abstracts in Madrid on darovasertib and IDE849. Darovasertib data will cover Phase 2/3 OptimUM-02 (HLA*A2:01-negative metastatic uveal melanoma), Phase 2 OptimUM-01 (HLA*A2:01-positive), and Phase 2 OptimUM-09 (neoadjuvant). Partner Hengrui will present long-term Phase 1 IDE849 (SHR-4849) results in relapsed SCLC and NECs.
How this was made
The 30-second read
Why it matters
This is a pipeline visibility update that may support bullish positioning for darovasertib and IDE849 into ESMO, but it does not introduce new clinical outcomes or financial/regulatory catalysts.
Market read
The release previews ESMO poster content for IDEAYA’s lead clinical programs, which can modestly improve sentiment but lacks new data to drive a major repricing today.
What to watch
Market reaction may depend on whether the ESMO posters include materially improved efficacy, safety signals, or biomarker-stratified results, none of which are provided here.
Background
IDEAYA is preparing ESMO 2026 poster presentations covering darovasertib across multiple uveal melanoma trials and an IDE849 (SHR-4849) Phase 1 DLL3 ADC program in SCLC/NECs via Hengrui.
Ticker impact
IDEAYA announced three ESMO 2026 poster presentations for darovasertib (OptimUM-02/01/09) and a Phase 1 IDE849 (SHR-4849) update via partner Hengrui.
Likely modest, sentiment-driven support into ESMO, with limited immediate repricing absent new data.
The article is a scheduling and content preview for upcoming ESMO posters, including trial names and settings, but it does not disclose new numerical outcomes, regulatory milestones, or financing changes.
Market effects
Adds incremental visibility into uveal melanoma and DLL3 ADC development, but without new readouts it is unlikely to shift broader sector expectations.
Primarily US-listed biotech sentiment; partner Hengrui activity is China-based but presented as an abstract preview.
ESMO timing may influence European oncology conference positioning, though the release itself is not a global macro driver.
Counterpoint
Because the release is only about planned abstracts, traders may overestimate near-term impact; the real catalyst will be the actual ESMO data release.
Key entities
- companyIDEAYA Biosciences
US-listed precision oncology company announcing ESMO 2026 abstract presentations for darovasertib and IDE849.
- drug_programDarovasertib
IDEAYA small-molecule oncology candidate with multiple OptimUM uveal melanoma trials highlighted.
- clinical_trialsOptimUM-02 / OptimUM-01 / OptimUM-09
Phase 2/3 and Phase 2 darovasertib trials in HLA-A2-negative and HLA-A2-positive metastatic uveal melanoma, plus neoadjuvant primary UM.
- drug_programIDE849 (SHR-4849)
DLL3 TOP1 ADC Phase 1 program in relapsed SCLC and other NECs presented by partner Hengrui.
- partnerHengrui Pharma
Partner presenting IDE849 Phase 1 long-term results at ESMO and targeting registrational trial initiation by year-end in China.
